Cargando…

Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy

PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were include...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hae Min, Hasanuzzaman, Md., Kim, So Won, Koh, Hyoung Jun, Lee, Sung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094525/
https://www.ncbi.nlm.nih.gov/pubmed/35544533
http://dx.doi.org/10.1371/journal.pone.0268353
_version_ 1784705557080309760
author Kang, Hae Min
Hasanuzzaman, Md.
Kim, So Won
Koh, Hyoung Jun
Lee, Sung Chul
author_facet Kang, Hae Min
Hasanuzzaman, Md.
Kim, So Won
Koh, Hyoung Jun
Lee, Sung Chul
author_sort Kang, Hae Min
collection PubMed
description PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group. RESULTS: Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0–21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6–2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7–3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0–20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0–21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3–4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0–7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively). CONCLUSION: The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR.
format Online
Article
Text
id pubmed-9094525
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-90945252022-05-12 Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy Kang, Hae Min Hasanuzzaman, Md. Kim, So Won Koh, Hyoung Jun Lee, Sung Chul PLoS One Research Article PURPOSE: Endothelin-1 (ET-1) is a potent vasoconstrictor which seems to be involved in the pathogenesis of diabetic retinopathy (DR). However, studies on intraocular ET-1 in DR have been limited. Thus, we investigated aqueous ET-1 levels in patients with DR. METHODS: A total 85 subjects were included in this prospective study. Those were classified into three groups: advanced DR group included those with severe nonproliferative DR or proliferative DR, whereas early DR group included those with mild nonproliferative DR or moderative nonproliferative DR. Those who underwent cataract surgery and had no concomitant ocular disease were included in the control group. Aqueous humor levels of ET-1 were obtained before intravitreal bevacizumab injection (IVB) and after 1 month for the DR patients, and at the time of cataract surgery for the control group. RESULTS: Advanced DR group included 40 eyes (47.1%), whereas early DR group did 19 eyes (22.4%), and control group (26 eyes, 30.5%). Mean aqueous ET-1 level was 10.1±4.1 pg/mL (6.0–21.0 pg/mL) in advanced DR group, 1.9±0.7 pg/mL (0.6–2.8 pg/mL) in early DR group, and 2.1±1.0 pg/mL (0.7–3.9 pg/mL) in control group (P < 0.001). Advanced DR group was further subdivided into severe nonproliferative DR (15 eyes, 12.8%) and proliferative DR (25 eyes, 34.3%). Mean aqueous ET-1 level was 10.1±4.3 pg/mL (6.0–20.1 pg/mL) in patients with severe nonproliferative DR, and 10.0±4.0 pg/mL (6.0–21.0 pg/mL) in those with proliferative DR (P = 0.928) at baseline. Mean ET-1 level at 1 month after intravitreal injection was 2.5±1.0 pg/mL (0.3–4.8 pg/mL) in patients with severe proliferative DR and 2.9±1.7 pg/mL (1.0–7.0 pg/mL) in those with proliferative DR (P = 0.443). Mean aqueous ET-1 level was significantly reduced in both groups (P < 0.001, respectively). CONCLUSION: The mean aqueous ET-1 level was significantly higher in the eyes with advanced DR than those with early DR and the control group. The mean aqueous ET-1 level was significantly reduced after intravitreal injections in the advanced DR group. Based on our results, future studies on the exact role of ET-1 in the pathogenesis of DR and future implication for intervention would be helpful for managing DR. Public Library of Science 2022-05-11 /pmc/articles/PMC9094525/ /pubmed/35544533 http://dx.doi.org/10.1371/journal.pone.0268353 Text en © 2022 Kang et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kang, Hae Min
Hasanuzzaman, Md.
Kim, So Won
Koh, Hyoung Jun
Lee, Sung Chul
Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title_full Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title_fullStr Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title_full_unstemmed Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title_short Elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
title_sort elevated aqueous endothelin-1 concentrations in advanced diabetic retinopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094525/
https://www.ncbi.nlm.nih.gov/pubmed/35544533
http://dx.doi.org/10.1371/journal.pone.0268353
work_keys_str_mv AT kanghaemin elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy
AT hasanuzzamanmd elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy
AT kimsowon elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy
AT kohhyoungjun elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy
AT leesungchul elevatedaqueousendothelin1concentrationsinadvanceddiabeticretinopathy